Oct 15, 2021 | 2021, Events, Scientific
Stifel Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri through a series of one-on-one meetings. Co-founder, CEO and CSO, Prof. Dario Neri is giving a presentation on November 16,...Oct 15, 2021 | 2021, Press Releases, Scientific
Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...Oct 13, 2021 | 2021, Press Releases, Scientific
Philogen S.p.A. announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune diseases. Read moreOct 5, 2021 | 2021, Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site. The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis...Oct 5, 2021 | 2021, Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...Oct 5, 2021 | 2021, Events, Scientific
Philogen is presenting a ePoster on the results of the run-in part of the Phase II study with Fibromun plus Dacarbazine for patients with in third or later line advanced/metastatic soft tissue sarcoma. See here for more details.
Recent Comments